Your browser doesn't support javascript.
loading
Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial.
Jiang, Haiping; Zheng, Yulong; Qian, Jiong; Mao, Chenyu; Xu, Xin; Li, Ning; Xiao, Cheng; Wang, Huan; Teng, Lisong; Zhou, Hui; Wang, Shuyan; Zhu, Donglei; Peng, Bo; Shen, Lin; Xu, Nong.
Afiliación
  • Jiang H; Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, No. 79, 86 Qingchun Road, Hangzhou, 310003, China.
  • Zheng Y; Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, No. 79, 86 Qingchun Road, Hangzhou, 310003, China.
  • Qian J; Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, No. 79, 86 Qingchun Road, Hangzhou, 310003, China.
  • Mao C; Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, No. 79, 86 Qingchun Road, Hangzhou, 310003, China.
  • Xu X; Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, No. 79, 86 Qingchun Road, Hangzhou, 310003, China.
  • Li N; Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, No. 79, 86 Qingchun Road, Hangzhou, 310003, China.
  • Xiao C; Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, No. 79, 86 Qingchun Road, Hangzhou, 310003, China.
  • Wang H; Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, No. 79, 86 Qingchun Road, Hangzhou, 310003, China.
  • Teng L; Department of Surgical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
  • Zhou H; Department of Medical Science and Strategy Oncology, Innovent Biologics, Inc, Suzhou, China.
  • Wang S; Department of Medical Science and Strategy Oncology, Innovent Biologics, Inc, Suzhou, China.
  • Zhu D; Department of Medical Science and Strategy Oncology, Innovent Biologics, Inc, Suzhou, China.
  • Peng B; Department of Translational Medicine, Innovent Biologics, Inc, Suzhou, China.
  • Shen L; Department of Medical Oncology, Beijing Cancer Hospital, Beijing, China.
  • Xu N; Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, No. 79, 86 Qingchun Road, Hangzhou, 310003, China. Nongxu.zhjph@outlook.com.
BMC Cancer ; 20(1): 760, 2020 Aug 14.
Article en En | MEDLINE | ID: mdl-32795349
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias Gástricas / Adenocarcinoma / Protocolos de Quimioterapia Combinada Antineoplásica / Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos / Anticuerpos Monoclonales Humanizados Tipo de estudio: Clinical_trials / Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: BMC Cancer Asunto de la revista: NEOPLASIAS Año: 2020 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias Gástricas / Adenocarcinoma / Protocolos de Quimioterapia Combinada Antineoplásica / Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos / Anticuerpos Monoclonales Humanizados Tipo de estudio: Clinical_trials / Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: BMC Cancer Asunto de la revista: NEOPLASIAS Año: 2020 Tipo del documento: Article